Amgen’s $3.7bn ChemoCentryx Buy May Help Offset Growing Pains

Big Biotech’s Q2 Revenue Was 1% Above Consensus

05 Aug 2022

Amgen believes it can more rapidly grow ChemoCentryx's Tavneos sales • Source: Shutterstock